Prolonged exposure to a topoisomerase I inhibitor may increase expression of topoisomerase II, making cells more susceptible inhibitors of that enzyme. This study was undertaken to establish the maximum tolerated dose (MTD) of a topotecan/topoisomerase II inhibitor sequential combination that may be active in acute leukemia, and to evaluate the effects of in vivo exposure to topotecan on topoisomerase II levels in leukemic blast cells as measured by image cytometry. Patients who were eligible for this phase I study had relapsed or refractory acute myeloid leukemia (р2 prior regimens) or CML blast crisis (0 or 1 prior regimen). Topotecan was given as a 5 day continuous i.v. infusion and was to be escalated through three levels (1.5, 1.75 and 2.0 mg/m 2 day), followed by etoposide at two dose levels (100 and 150 mg/m 2 ) i.v. bolus days 6, 7 and 8. Topoisomerase II␣ levels in leukemic blasts from bone marrow were measured by image cytometry prior to starting treatment, on day 5 of topotecan infusion and on day 28; and daily during topotecan in peripheral blood blasts. Dose-limiting toxicity was seen in two of six patients at the first dose level (topotecan 1.5 mg/m 2 /day, etoposide 100 mg/m 2 /day; уgrade 3 mucositis in both cases). This cohort was expanded to 10 patients; no further non-hematologic dose-limiting toxicity was observed, but given the extent of toxicity seen, further dose escalation was judged not to be feasible. Topo II␣ levels increased in peripheral blood blasts during the first 72 h of topotecan infusion and returned to near baseline by day 5, whereas levels appeared to decrease in bone marrow blasts by day 5 compared to pretreatment. One complete hematologic and cytogenetic remission in a patient with CML blast crisis was observed in the 10 patients evaluable for response. The sequential administration of topotecan 1.5 mg/m 2 /day continuous infusion for 5 days followed by etoposide 100 mg/m 2 /day × 3 is the recommended phase II dose for this schedule. Topotecan increases topo II␣ expression in vivo in leukemia cells, but levels of the enzyme are cell cycle dependent. Pharmacodynamic evaluation of the sequential or combination administration of novel antileukemic agents may help improve treatment strategies in acute leukemia.
Introduction
Topotecan is a semi-synthetic water soluble analogue of camptothecin, which inhibits the nuclear enzyme topoisomerase I. This novel chemotherapy agent has shown broad activity in solid tumors, especially carcinomas of the lung and ovary. 1 In preclinical studies, topotecan was highly active in mice bearing L1210 leukemia. 2 Experimental data suggested that prolonged exposure to topotecan may result in greater activity compared to bolus administration. 3 Levels of topoisomerase I may be higher in malignant cells and in cells which are actively dividing. 4, 5 Preclinical data suggest that the combination of a topoisomerase II active agent with topoisomerase I inhibition by topotecan produces synergistic cell killing in vitro and in vivo. 6, 7 Sequential administration of topotecan followed by a topoisomerase II inhibitor may lead to increased activity of the latter drug through increased expression of topoisomerase II. Hendricks et al 8 have shown that resistance to topotecan may be mediated by p-glycoprotein, an important mechanism of drug resistance in AML. However, the effect of p-glycoprotein overexpression on topotecan accumulation in cells is substantially smaller than on the accumulation and cytotoxicity of daunorubicin or VP16 in the same cell line. 8 Topotecan remained active in p-glycoprotein expressing tumour xenografts in vivo. 9 Two phase I studies of topotecan in acute leukemia, given as a 5 day continuous infusion, have been reported. 10, 11 These studies have suggested that the maximum tolerated dose is 2.0-2.3 mg/m 2 /day for 5 days, and the dose-limiting toxicity is mucositis. No other significant nonhematologic toxicity was observed. Responses were seen in heavily pre-treated patients, indicating that topotecan may have important activity in leukemia. The primary goal of the present study was to establish the maximum tolerated dose of a topotecan/topoisomerase II inhibitor combination which might be incorporated in primary therapy of acute myeloid leukemia. We chose etoposide as the topoisomerase II inhibitor for this study because of its demonstrated activity in AML 12 and because most patient treated at our institutions are not routinely exposed to this drug during initial therapy. A secondary goal was to evaluate the effect of the administration of topotecan on the expression of topoisomerase II in leukemic blasts from marrow and peripheral blood of patients with AML.
Methods

Eligibility criteria
Patients were eligible for this trial if they had relapsed or refractory acute myeloid leukemia and had received one or two prior regimens. Patients with chronic myeloid leukemia (CML) in blast phase and patients with secondary acute myeloid leukemia following a diagnosis of myelodysplasia (MDS) who were previously untreated or had received one prior regimen were also eligible. Those who had previously received an autologous or allogeneic bone marrow transplant were excluded. Additional eligibility criteria included an ECOG performance status р2, serum creatinine р1.5 times the upper limit of normal, normal serum bilirubin and a left ventricular ejection fraction measured by a MUGA scan у40%. Those with active or uncontrolled infection or with treatment-related acute myeloid leukemia were excluded. This trial was approved by the human research ethics committees of the University of Toronto, The Toronto Hospital and Princess Margaret Hospital, and all patients provided written informed consent.
Treatment plan
All patients were treated in hospital and chemotherapy was administered through an indwelling Hickman catheter. Topotecan was administered by 24 h continuous infusion on days 1-5 (120 h infusion total), followed by etoposide given over 1 h on days 6, 7 and 8. Because mucositis was anticipated to be the dose-limiting toxicity of this combination, the initial topotecan dose was set below the previously established MTD (2.0 mg/m 2 /day for 5 days). The starting dose of topotecan was 1.5 mg/m 2 /day, and etoposide 100 mg/m 2 daily, with the intention of escalating topotecan to 1.75 mg and 2.0 mg/day, followed by escalation of etoposide through two-dose levels to 150 mg/day. Does-limiting toxicity was defined as NCIC-CTG grade у3 renal, hepatic or gastrointestinal toxicity (the latter lasting 3 or more days); any sign of congestive heart failure or arrhythmia; у grade 3 central nervous system toxicity or skin rash; or grade 2 pulmonary toxicity. In this study hematologic doselimiting toxicity was defined as pancytopenia with a hypocellular marrow (р5% cellular and no marrow blasts) lasting more than 6 weeks from the start of treatment. If two or more patients of the first three treated at a given dose level experienced DLT then that level was considered the maximum tolerated dose, and the next lower dose level would be expanded by a further three patients. Patients experiencing anti-leukemia effects could be retreated after recovering from a prior course if there was no DLT in that patient; a reduction of one dose level was required if DLT had occurred in that patient in the first cycle. Dosage calculations were made on the basis of actual height and weight. Supportive care during therapy was according to usual institutional practice, and included red blood cell transfusion for Hb Ͻ80 g/l and platelet transfusion for counts Ͻ20 × 10 9 /l. Criteria for complete and partial remission were the same as those used previously. 13 Patients with CML were considered to have achieved complete remission if their blood counts and bone marrow were normal, even if the Philadelphia chromosome persisted in cytogenetic analysis.
Topoisomerase measurements
Assessment of leukemic blast cell topoisomerase II levels was performed as described previously.
14 Briefly, cytospin preparations of leukemia cell lines (provided by Dr M Freedman, Toronto) expressing high levels and low levels of topoisomerase II were used as positive and negative controls. Bone marrow smears from study patients were made prior to treatment and on day 5 of the topotecan infusion. Peripheral blood films were made daily during topotecan infusion from patients in whom circulating blasts were present and were analyzed similarly. Slides were air dried, fixed in neutral-buffered formalin for 10 min and stored at −20°C.
At the time of processing the slides were pre-treated with 1% 2-mercaptoethanol and 0.1% SDS for 10 min at room temperature, rinsed, permeabilized with cold methanol for 2 min and then incubated in a humid chamber for 3 h with anti-topo II␣ (P170) antibody (TopoGEN, Columbus, OH, USA) diluted 1:50. After rinsing, the slides were incubated for 3 h in a dark humid chamber with a 1:150 dilution of secondary antibody, F(abЈ) 2 anti-rabbit antibody (Cedarlane, Hornby, Ontario, Canada). Counterstaining of nuclear DNA was done with 8 mol DAPI (4,6-diamino-2-phenylindole) for 30 min. The slides were then cover-slipped with a glycerol based mountant with 2.3% 1,4-diazabicyclo[2-2-2]octane (DABCO) made up in 90% glycerol and stored in the dark at 4°C.
A quantitative immunofluorescence method was used to measure nuclear topo II␣ antibody labelling, as previously described.
14 Analysis was performed using an Olympus, Mississauga, Ontario, Canada fluoroscope fitted with an intensified CCD camera interfaced with a SAMBA 4000 image cytometer. Using 330-385 nm excitation and 420 nm barrier filter cube, DAPI staining was used to create a nuclear mask. The same field was then viewed with 470-490 nm excitation and 515 nm barrier filter cube to measure antibody binding. The DAPI nuclear mask was then overlaid on this image so that only specific nuclear immunofluorescence was measured.
14 Only the nuclei of large blast-like cells were assessed in both bone marrow and peripheral blood. Depending on the cellularity of the sample, between 200 and 900 cells were measured for each slide. Results for antibody labelling were expressed as the integrated fluorescence, which corresponds to the total amount of enzyme protein in the nucleus. Slides from the same batch of fixed, frozen ALL cells were used as controls and standards for each staining run, and the results for patients were expressed as relative values.
Results
Eleven patients were enrolled on this trial. Their characteristics are summarized in Table 1 . All of the patients with AML had previously received high-dose Ara-C, either as initial induction therapy or at first relapse. The first patient entered at dose level I was diagnosed with CNS leukemia on day 2 of the topotecan infusion, and required intrathecal chemotherapy; therefore this patient was inevaluable for toxicity. One of the next three patients enrolled at the first level experienced grade 3 diarrhea and grade 4 stomatitis requiring intravenous narcotics and total parenteral nutrition for 10 days. Four more patients were then added to the first dose level, and a second patient encountered dose-limiting toxicity (grade 3 mucositis requiring intravenous narcotics for 7 days). There did not seem to be any clear relationship between the occurrence of grade 3 gastrointestinal toxicity, and the degree of pretreatment of the initial seven patients enrolled at the first 18-42+ ). This degree of myelosuppression is comparable to that seen in our centers with other second-line leukemia protocols. After review of the toxicity of this group of 10 evaluable patients, it was felt that enrollment of patients at the next dose level of 1.75 mg/m 2 of topotecan and 100 mg/m 2 was likely to result in unacceptable gastrointestinal toxicity and further dose escalation could not be justified. Therefore, dose level I was determined to be the recommended dose for further phase II evaluation. Nonhematologic toxicity experienced by all evaluable patients is summarized in Table 2 .
Of the 10 patients evaluable for response, there was one complete hematologic and cytogenetic remission in a patient with previously untreated CML blast crisis. This remission lasted for 3. months following a second cycle of topotecan and etoposide (with no DLT observed). Peripheral blood blasts disappeared in all patients following completion of protocol therapy, except for the woman with CNS progression; however, this was transient.
Topoisomerase II analysis
A total of nine patients had bone marrow samples both prior to treatment and on day 5 of the topotecan infusion available for analysis. One patient demonstrated a large increase in topoisomerase II␣ relative to baseline following topotecan administration, whereas with the remaining eight patients there was either no significant change or a decrease in enzyme level (Figure 1 ). Although most patients showed a marked decrease in the number of circulating leukemia cells during the 5 day topotecan infusion, sufficient cells remained to make sequential measurements on peripheral blood cells daily. Analysis of blasts in the peripheral blood obtained on each day of topotecan infusion showed an approximate threefold rise in peripheral blood topoisomerase II␣ levels relative to baseline although there was considerable inter-patient variability, as indicated by the wide spread in inter-quartile values shown in Figure 2 . Maximum enzyme expression Table 2 Non-hematologic toxicity (n = 10) appeared on about day 3, followed by a decrease to near baseline by day 5.
Discussion
Only two classes of drugs have demonstrated significant activity in AML, and they form the basis of current induction chemotherapy regimens. These are the nucleoside analogues such as cytosine arabinoside (Ara-C), which interfere with DNA synthesis by inhibition of DNA polymerase; and inhibitors of the nuclear enzyme topoisomerase II, such as daunorubicin, idarubicin, mitoxantrone, and etoposide. The newer analogues of daunorubicin have produced only modest improvement in remission rate, remission duration and survival. 15 Promising results have been obtained by the addition of fludarabine to Ara-C, but the use of this agent as part of remission induction strategies has not yet produced improved results over Ara-C alone. 16, 17 Although post-remission strategies such as use of high-dose Ara-C 18 or allogeneic or autologous bone marrow transplantation 19 may improve the longterm outcome of patients under the age of 50 or 60, not all trials have shown this. 20, 21 Many patients are not eligible for these approaches because of age, performance status, lack of donor, or relapse before bone marrow transplantation. Longterm follow-up data show that the majority of patients with acute myeloid leukemia treated with chemotherapy ultimately relapse and very few are cured. 22 Phase I trials have shown that significant escalation of topotecan above doses that can be tolerated in patients with solid tumors are feasible in patients with leukemia, and have suggested that this drug is active in previously treated patients. 10, 11 Previous work by Rowinsky et al 11 suggests that levels of the target enzyme for topotecan, topoisomerase I, are higher in AML and ALL blast cells than in bone marrow mononuclear cells, although the number of patients studied was small. Expression of the enzyme in AML cells appeared to be fairly homogeneous in their study, suggesting that topoisomerase I would be an appropriate target for anti-leukemic therapy. Although Rowinsky et al did not find a correlation between the percentage of cells in the S and G 2 M phases of the cell cycle and topoisomerase I content, 11 others have shown that topoisomerase I levels are higher in cycling compared to non-cycling cells. 5 Inhibition of topoisomerase I by camptothecin analogues is believed to result in a compensatory increase in topoisomerase II activity. 23 Our data are the first to demonstrate changes in topoisomerase II␣ levels in leukemic blast cells after in vivo exposure to a topoisomerase I inhibitor. A rise in nuclear staining for topo II␣ was observed over the initial 2-3 days of the drug infusion, but declined toward the end of the 5 days of topotecan. In contrast, after 5 days, bone marrow blasts exhibited levels of expression of topoisomerase II␣ that were lower than or unchanged from baseline. Because bone marrow was sampled only on day 5, it is unclear if the increase in topoisomerase II␣ levels that was seen in peripheral blood blasts would also have been observed if bone marrow had been sampled earlier in the topotecan infusion period. Since the absolute number of blast cells in the peripheral blood fell throughout the course of the topotecan infusion, the apparent decline in topoisomerase II␣ may reflect analysis of a different subpopulation of cells with respect to phase of the cell cycle. Levels of topoisomerase II rise steadily through the S and G 2 M phases of the cell cycle in acute lymphoblastic leukemia cell lines and are lowest in non-cycling cells; 14 this relationship was much less obvious in samples from patients in this study, however. A greater proportion of cells in both the blood and bone marrow are in G 0 at the end of the topotecan infusion, compared to pretreatment (data not shown). The number of patients analyzed in this phase I study is small, however, and further evaluation of this relationship is important. Acute leukemia appears to be an ideal model for evaluating the kinetics of important target enzymes in cancer chemotherapy and their relationship to the cell cycle using image cytometry. Although the number of patients treated was small, we did observe one complete hematological and cytogenetic remission in a patient with CML blast crisis. All other patients with leukemic cells in their peripheral blood experienced clearing of their blast cells, although this was transient and in no other patient was even a partial remission observed. This may reflect the fact that the LD90 values for topotecan for leukemic cells from patients grown in leukemia colonyforming assays is very similar to the steady-state concentrations of the active drug obtained when the drug is given by continuous infusion. 10 Given the modest gains achieved in the last two decades in the therapy of adult acute myeloid leukemia, evaluation of new cytotoxic agents with novel mechanisms of action remains a priority in this disease. The single agent activity demonstrated in AML, ALL and myelodysplasia suggests that inhibitors of topoisomerase I such as topotecan are likely to find a place in the treatment of acute leukemia. 24 We are currently evaluating the antileukemic activity and biologic effects of the combination of topotecan 1.5 mg/m 2 /day for 5 days continuous i.v. infusion, followed by etoposide 100 mg/m 2 / day × 3 (the MTD from this trial) in a phase II study in relapsed and refractory AML in a less heavily pre-treated patient population. Investigation of topotecan in combination with other topoisomerase II inhibitors or with Ara-C 25 appears warranted.
